Related Experiment Video
Updated: Dec 10, 2025

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
Published on: November 16, 2016
Azithromycin: The First Broad-spectrum Therapeutic
Anton Firth1, Praveen Prathapan1
1New Biochemistry, University of Oxford, South Parks Road, Oxford, OX1 3QU, UK.
Abstract:
The Strategic Plan for Biodefense Research by the U.S. Department of Health and Human Services demarcates the need for drugs which target multiple types of pathogens to prepare for infectious threats. Azithromycin is one such broad-spectrum therapeutic that is both included in the University of Oxford's RECOVERY and excluded from the World Health Organization's SOLIDARITY trials. Here we review azithromycin's broad antibiotic, antimalarial, antiviral pharmacology and contextualise it against a broader history as the most repositioned therapeutic of the macrolide class; we further evaluate azithromycin's clinical and socio-economic propriety for respiratory pandemics and delineate a model for its combinatorial mechanism of action against COVID-19 pneumonia.
Related Concept Videos
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Development of Antibiotic Resistance
Antibiotic Selection
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Antimicrobial Effectiveness

